Педиатрическая фармакология (Sep 2013)

CLINICAL CASE OF CANAKINUMAB USE IN A PATIENT WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

  • R. V. Denisova,
  • E. I. Alexeeva,
  • T. V. Sleptsova

DOI
https://doi.org/10.15690/pf.v10i5.835
Journal volume & issue
Vol. 10, no. 5
pp. 111 – 114

Abstract

Read online

The article presents a case of successful use of therapeutic monoclonal antibodies to interleukin 1 (canakinumab) at severe systemic juvenile idiopathic arthritis. Canakinumab treatment promptly provided reduction in clinical and laboratory disease activity indicators, increase in life quality, development of inactive disease stage and allowed avoiding prescription of glucocorticoids.

Keywords